ITI Pharma and Healthcare Fund
NAV
₹19.45
as of 6 Oct 2026
ITI Pharma and Healthcare Fund is an open-ended Sectoral/ Thematic scheme from ITI Mutual Fund managing ₹276 crore (as of 31 Aug 2026). Its Direct-plan NAV is ₹19.45 as of 6 Oct 2026. The expense ratio is 0.92% a year. Managed by Rohan Korde. This page is factual data only – it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.92% / yr
- as of 31 Aug 2026
- Fund size
- ₹276 crore
- as of 31 Aug 2026
- Exit load
- 0.5%
- SIP available
- Yes
- Launched
- 11 Nov 2021
- ISIN
- INF00XX01BO9
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from nyvo’s own NAV data.
Rebased to 100data to 5 Oct 2026Benchmark: Nifty 500 Healthcare TRI
ITI Pharma and Healthcare Fund
₹192
+92% on ₹100 over 4.9 yrs
Sectoral/ Thematic average
₹205
+105% on ₹100 over 4.9 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 0.23% | -4.47% | +4.70 |
| 6 months | 17.60% | 7.56% | +10.04 |
| 1 year | 10.34% | -0.10% | +10.44 |
| 3 years (CAGR) | 19.02% | 12.32% | +6.70 |
| 5 years (CAGR) | 14.27% | 11.84% | +2.43 |
Category average across 119 funds, as of 5 Oct 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible – read that number first.
1-year holding periods
- Worst
- -9.1%
- Median
- 13.4%
- Best
- 61.1%
48 windows over the last 59 months, stepped monthly; 77% ended positive. Worst window began 1 Jan 2025. Windows overlap – this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 18.9%
- Median
- 21.3%
- Best
- 26.0%
24 windows over the last 59 months, stepped monthly; 100% ended positive. Worst window began 1 Feb 2023. Windows overlap – this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.88
- Sortino ratio (3Y)
- 1.45 vs category 1.63
- Standard deviation (3Y)
- 16.42%
- Beta (3Y)
- 0.99
- Alpha (3Y)
- -1.11%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high – how deep and for how long is what a drawdown feels like.
Deepest fall
-16.1%
Right now
-5.3% below peak
Ahead of its benchmark in 42% of months (window: 3y, monthly) – benchmark: Nifty 500 Healthcare TRI, name shown only.
Where the money actually is
Equity
99.3%
Cash
0.7%
Whole-portfolio split, as of 31 Aug 2026.
What it owns
38 positions · top 10 = 57.0%
Market-cap mix
Large 36.5%Mid 40.0%Small 22.8%Other 0.7%
as of 31 Aug 2026
Holdings by sector
Healthcare(10 in top 10)97.0%
- Sun Pharmaceuticals Industries Ltd12.58%
- Divi's Laboratories Ltd9.23%
- Apollo Hospitals Enterprise Ltd5.72%
- Max Healthcare Institute Ltd Ordinary Shares4.84%
- Torrent Pharmaceuticals Ltd4.75%
- Dr Reddy's Laboratories Ltd4.31%
- Cipla Ltd4.22%
- Laurus Labs Ltd4.02%
- Aurobindo Pharma Ltd3.97%
- Mankind Pharma Ltd3.31%
- Basic Materials2.3%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Aug 2026. Portfolio turnover 40.7% vs category 37.4% a year.
The businesses it owns
- P/E (trailing)
- 44.3 vs category 25.9
- P/B
- 6.4 vs category 3.9
- Dividend yield
- 0.6% vs category 1.1%
- Net margin
- 15.4% vs category 15.4%
- Earnings growth
- 17.2%
- Avg market cap
- ₹88,448 crore
Money in, money out
- Net flow, 3 months
- +₹10 cr
as of 31 Aug 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of ITI Pharma and Healthcare Fund?
- ₹19.45 per unit as of 6 Oct 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of ITI Pharma and Healthcare Fund?
- 0.92% a year for the Direct plan, as of 31 Aug 2026.
- How large is ITI Pharma and Healthcare Fund?
- ₹276 crore under management as of 31 Aug 2026, in the Sectoral/ Thematic category.
- How risky is ITI Pharma and Healthcare Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of ITI Pharma and Healthcare Fund?
- 14.27% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 11.84%. Past returns do not predict future returns.
- What is the worst 3-year return of ITI Pharma and Healthcare Fund?
- 18.9% a year – the weakest of 24 overlapping 3-year holding periods, beginning 1 Feb 2023. The median was 21.3% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages ITI Pharma and Healthcare Fund?
- Rohan Korde, managing this fund for 4.4 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund – growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,338 crore
- ICICI Prudential Business Cycle Fund₹15,873 crore
- ITI Banking and Financial Services Fund₹388 crore
- ITI Bharat Consumption Fund₹370 crore
- quant ESG Integration Strategy Fund₹319 crore
- Edelweiss Financial Services Fund₹289 crore
- Kotak Energy Opportunities Fund₹275 crore
- LIC MF Banking and Financial Services Fund₹275 crore
Data: nyvo research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.